Abstract:Merozoite surface protein 1 of Plasmodium falciparum (PfMSP-1) is regarded as a key candidate antigen for malaria vaccine development. It exhibits significant antigenic polymorphism and has been divided into 17 building blocks based on the analysis of sequence diversity. Differences in the antigenic composition of PfMSP-1 in local P. falciparum populations may result in differences in the efficacy of vaccines, which contain sequences of particular allelic variant(s) of PfMSP-1. To contribute to the required knowledge of genetic diversity of malaria parasites in geographically diverse regions, we have used the polymerase chain reaction (PCR) to analyze the sequence diversity of blocks 1–4 of PfMSP-1 in disease isolates from the Kilombero District in Tanzania. In the semi-conserved block 1, in which dimorphic amino acid variances have been described at three positions, we found three of the five previously described combinations of these three pairs of amino acids. In addition one combination was found, which has not been reported before in parasite isolates from different locations worldwide. Of the two sequence variants, which were dominating, one (S44-Q47-V52) corresponded to the 83.1 sequence incorporated into the SPf66 malaria peptide vaccine, while the other one (G44-H47-I52) differed from the previous in all three dimorphic amino acids. The partial protection observed in a phase III SPf66 trial conducted in the Kilombero District in children aged 1–5, thus does not seem to be associated with a clear dominance of favourable variants of block 1 of PfMSP-1 in this area. All three different principle types of block 2, the major polymorphic region of PfMSP-1, were found in the Tanzanian isolates. Most of the sequences contained K1-type tripeptide repeats, but clones with MAD20-type repeats or no repetitive sequence (RO33-type block 2) were also present. K1- and MAD20-type tripeptide repeat motifs were never mixed within one parasite clone. In one sequence a hexapeptide repeat was found at the end of block 2, which has not been reported before. Dimorphism in 13 of the 17 previously described variable positions of the semi-conserved block 3 and three of four recombination types of block 4 (K/K, M/K and M/M) were found among the Tanzanian isolates. Apart from previously described dimorphic amino acid positions, polymorphism was rare in the non-repeated building blocks. Selection and spreading of parasite variants, which contain amino acid exchanges at other than the dimorphic positions thus, is not a common event. Parasite isolates frequently harboured more than one PfMSP-1 allele. Three of the four heterogeneous isolates analysed contained two different general types of sequences. One isolate contained at least four distinct clones, demonstrating the high endemicity of malaria in the Kilombero District, which is a well-established site for malaria vaccine field trials.

Solution structure of a Plasmodium falciparum AMA-1/MSP 1 chimeric protein vaccine candidate (PfCP-2.9) for malaria

Fusion of Two Malaria Vaccine Candidate Antigens Enhances Product Yield, Immunogenicity, and Antibody-Mediated Inhibition of Parasite Growth in Vitro

Blood-Stage Vaccine Candidate of Plasmodium Falciparum

Epitope Mapping of PfCP-2.9, an Asexual Blood-Stage Vaccine Candidate of Plasmodium Falciparum

A Phase 1 Trial of Pfcp2.9: an Ama1/Msp1 Chimeric Recombinant Protein Vaccine for Plasmodium Falciparum Malaria

Evaluation of Three Pichia Pastoris-Expressed Plasmodium Falciparum Merozoite Proteins As A Combination Vaccine Against Infection with Blood-Stage Parasites

Preclinical evaluation of a chimeric malaria vaccine candidate in Montanide ISA 720 (R)

Solution Conformation, Backbone Dynamics and Lipid Interactions of the Intrinsically Unstructured Malaria Surface Protein MSP2

[Influence of Deleting 9 Amino Acid Residues at N-terminus on Immunogenicity of a Plasmodium Falciparum Chimeric Protein].

Structure and Dynamics of Apical Membrane Antigen 1 from Plasmodium Falciparum Fvo

Stability and Potency of the Plasmodium Falciparum Msp1-19/Ama-1 (iii) Chimeric Vaccine Candidate with Montanide Isa720 Adjuvant

Role of the helical structure of the N-terminal region of Plasmodium falciparum merozoite surface protein 2 in fibril formation and membrane interaction.

[Preparation and Characterization of Monoclonal Antibody Specific to PfCP-2.9 Chimeric Protein of Plasmodium Falciparum].

Merozoite Surface Protein 2 of Plasmodium Falciparum: Expression, Structure, Dynamics, and Fibril Formation of the Conserved N-terminal Domain.

Design and Evaluation of Chimeric Plasmodium falciparum Circumsporozoite Protein-Based Malaria Vaccines

A Direct and Rapid Sequencing Strategy for the Plasmodium Falciparum Antigen Gene Gp190/msa1

Preclinical evaluation of a chimeric malaria vaccine candidate in Montanide ISA 720: immunogenicity and safety in rhesus macaques.

Construction of Transgenic Plasmodium Berghei As a Model for Evaluation of Blood-Stage Vaccine Candidate of Plasmodium Falciparum Chimeric Protein 2.9.

Immunogenicity of Plasmodium falciparum chimeric protein PfCP-2.9 in various strains of mice

Construction and evaluation of a multistage combination vaccine against malaria.

The molecular basis for peptide-based antimalarial vaccine development targeting erythrocyte invasion by P. falciparum